Demonstration of a common artifact in immunosorbent assays of brain extracts: Development of a solid-phase extraction protocol to enable measurement of amyloid-β from wild-type rodent brain

Journal of Neuroscience Methods

Volumn 157, Issue 1, 2006, Pages 71-81

  Lanz, Thomas A ^a   Schachter, Joel B ^a  

^a PFIZER INC   (United States)

Author keywords

Abeta; Alzheimer's disease; Amyloid beta; Brain homogenate; ELISA; Nonspecific binding; Solid phase extraction

Indexed keywords

AMYLOID BETA PROTEIN; BRAIN EXTRACT; PEPTIDE ANTIBODY; SEPHADEX; SYNTHETIC PEPTIDE;

ACCURACY; ANIMAL TISSUE; ANTIBODY DETECTION; ARTICLE; ARTIFACT; BRAIN; CEREBROSPINAL FLUID; COLORIMETRY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDY; FLUORESCENCE ANALYSIS; IMMUNOREACTIVITY; MALE; MOUSE; NONHUMAN; PEPTIDE ANALYSIS; PLASMA; PRIORITY JOURNAL; PROTEIN BINDING; QUANTITATIVE ANALYSIS; RAT; SEPARATION TECHNIQUE; SOLID PHASE EXTRACTION; WILD TYPE;

AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN; ANALYSIS OF VARIANCE; ANIMALS; ARTIFACTS; BINDING SITES, ANTIBODY; BLOTTING, WESTERN; BRAIN; BRAIN CHEMISTRY; DEXTRANS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MALE; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY; TISSUE EXTRACTS;

EID: 33748191750     PISSN: 01650270     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneumeth.2006.03.023     Document Type: Article

References (17)

1. Anderson J.J., Holtz G., Baskin P.P., Turner M., Rowe B., Wang B., et al. Reductions in beta-amyloid concentrations in vivo by the gamma-secretase inhibitors BMS-289948 and BMS-299897. Biochem Pharmacol 69 (2005) 689-698
2. Barten D.M., Guss V.L., Corsa J.A., Loo A.T., Hansel S.B., Zheng M., et al. Dynamics of beta-amyloid Reductions in brain, cerebrospinal fluid and plasma of beta-amyloid precursor protein transgenic mice treated with a gamma-secretase inhibitor. J Pharmacol Exp Ther 312 (2005) 635-643
3. Best J.D., Jay M.T., Otu F., Ma J., Nadin A., Ellis S., et al. Quantitative measurement of changes in amyloid-β(40) in the rat brain and cerebrospinal fluid following treatment. J Pharmacol Exp Ther 313 (2005) 902-908
4. Dovey H.F., John V., Anderson J.P., Chen L.Z., de Saint Andrieu P., Fang L.Y., et al. Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem 76 (2001) 173-181
5. Eckman E.A., Watson M., Marlow L., Sambamurti K., and Eckman C.B. Alzheimer's disease beta-amyloid peptide is increased in mice deficient in endothelin-converting enzyme. J Biol Chem 278 (2003) 2081-2084
6. Glenner G.G., Harada M., and Isersky C. The purification of amyloid fibril proteins. Prep Biochem 2 (1972) 39-51
7. Janus C., Chishti M.A., and Westaway D. Transgenic mouse models of Alzheimer's disease. Biochim Biophys Acta 1502 (2000) 63-75
8. Johnstone E.M., Chaney M.O., Norris F.H., Pascual R., and Little S.P. Conservation of the sequence of Alzheimer's disease amyloid peptide in dog, polar bear, and five other mammals by cross-species polymerase chain reaction analysis. Mol Brain Res 10 (1991) 299-305
9. Kaplan B., Hrncic R., Murphy C.L., Gallo G., Weiss D.T., and Solomon A. Microextraction and purification techniques applicable to chemical characterization of amyloid proteins in minute amounts of tissue. Methods Enzymol 309 (1999) 67-81
10. Kukar T., Murphy M.P., Eriksen J.L., Sagi S.A., Weggen S., Smith T.E., et al. Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production. Nat Med 11 (2005) 545-550
11. Kuo Y.M., Emmerling M.R., Lampert H.C., Hempelman S.R., Kokjohn T.A., Woods A.S., et al. High levels of circulating Aβ42 are sequestered by plasma proteins in Alzheimer's disease. Biochem Biophys Res Commun 257 (1999) 787-791
12. Lanz T.A., Himes C.S., Pallante G., Adams L., Yamazaki S., Amore B., et al. The gamma-secretase inhibitor N-[N-(3,5-difluorophenacetyl)-l-alanyl]-S-phenylglycine t-butyl ester reduces A beta levels in vivo in plasma and cerebrospinal fluid in young (plaque-free) and aged (plaque-bearing) Tg2576 mice. J Pharmacol Exp Ther 305 (2003) 864-871
13. Lanz T.A., Hosley J.D., Adams W.J., and Merchant K.M. Studies of Abeta pharmacodynamics in the brain, cerebrospinal fluid, and plasma in young (plaque-free) Tg2576 mice using the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-o xo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-l-alaninamide (LY-411575). J Pharmacol Exp Ther 309 (2004) 49-55
14. Matsumoto A., Minami M., and Matsumoto R. The beta-amyloid epitope masking activity in human brain is identified as albumin. Neuroreport 8 (1997) 3297-3301
15. Mehta P.D., Dalton A.J., Mehta S.P., Kim K.S., Sersen E.A., and Wiskniewski H.M. Increased plasma amyloid beta protein 1-42 levels in Down syndrome. Neurosci Lett 241 (1998) 13-16
16. Wood K.M., Du P., Geoghegan K.F., and Tate B. In vivo Aβ peptide profiling by immunoprecipitation and mass spectrometry. Soc Neurosci (2005) 568.8
17. Zou L.B., Mouri A., Iwata N., Saido T.C., Wang D., Wang M.W., et al. Inhibition of neprilysin by infusion of thiorphan into the hippocampus causes an accumulation of amyloid β and impairment of learning and memory. J Pharmacol Exp Ther 317 (2006) 334-340